Drugmaker Eli Lilly and Co. has developed a treatment for obesity that showed marked success in late-stage trials, helping study participants lose up to 52 pounds.
The drug, tirzepatide, was highly successful at three different doses, with subjects losing an average of about 35 pounds with the lowest dose, 49 pounds with a medium dose, and up to 52 pounds with the highest dose.
“Tirzepatide is the first investigational medicine to deliver more than 20% weight loss on average in a phase 3 study, reinforcing our confidence in its potential to help people living with obesity," said Jeff Emmick, the vice president of product development at Eli Lilly.The once-weekly injectable drug suppresses appetite and increases energy expenditure by mimicking the effects of two gut hormones called GLP-1 and GIP.
Tirzepatide will be going up against Novo Nordisk’s obesity drug Wegovy, a blockbuster injectable drug that helps people shed, on average, about 15% of their body weight. Wegovy ushered in billions in profits for the Danish drugmaker. Novo has projected that its obesity franchise will bring in about $3.5 billion by 2025.
They constitute a new class of obesity treatments after years of products with safety concerns and questionable science backing them up flooded the market. For that reason, doctors have often been apprehensive about prescribing treatments for obesity, while some insurance companies that do not consider obesity a disease have been quick to decline coverage.It is highly likely that tirzepatide will pull in major profits for Eli Lilly.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Eli Lilly finds 'huge opportunity' in drug that helps people shed up to 21% of weightPharmaceutical giant says new study yielded promising results on a treatment for the 110 million Americans who are obese.
Weiterlesen »
Eli Lilly shares gain after results beat estimates, obesity drug dataEli Lilly and Co on Thursday posted quarterly results that beat Wall Street estimates and said its experimental obesity drug met the main goal in a late-stage study, sending shares of the drugmaker up 4%.
Weiterlesen »
Seasons 52 to open 6th N.J. restaurantThe fresh grill and wine bar is best known for a menu that rotates seasonally
Weiterlesen »
Eli Lilly's strong quarter, promising obesity drug data show why we like the stockIt was another strong quarter and fantastic pipeline update from Eli Lilly, a best-in-class name in the pharmaceutical industry.
Weiterlesen »
Eli Lilly shares gain after results beat estimates, obesity drug dataEli Lilly and Co on Thursday posted quarterly results that beat Wall Street estimates and said its experimental obesity drug met the main goal in a late-stage study, sending shares of the drugmaker up 4%.
Weiterlesen »
Eli Lilly's strong quarter, promising obesity drug data show why we like the stockIt was another strong quarter and fantastic pipeline update from Eli Lilly, a best-in-class name in the pharmaceutical industry.
Weiterlesen »